Want to see FR:IVA full AI Analyst Report?
Inventiva (IVA) AI Stock Analysis
Top Page
Inventiva
(Paris:IVA)
Overall score reflects a tug-of-war between weak fundamentals and better near-term execution visibility: financial performance is the biggest drag (shrinking revenue, widening losses, ongoing cash burn, and negative equity), while the earnings call provides meaningful offset via clear Phase III/NDA timeline and improved runway. Technicals and valuation contribute only modestly given mixed signals and limited valuation interpretability with negative earnings.
Inventiva (IVA) vs. iShares MSCI France ETF (EWQ)
- Market Cap
- EUR 443.61M
- Dividend Yield
- ―
- Average Volume (3M)
- 515.57K
- Price to Earnings (P/E)
- -6.0
- Beta (1Y)
- 0.15
- Revenue Growth
- -99.64%
- EPS Growth
- 68.67%
- Country
- France
- Employees
- 87
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Inventiva Business Overview & Revenue Model
Company Description
Inventiva S.A. is a biopharmaceutical firm currently in the clinical development phase, specializing in creating orally administered small molecule treatments for conditions such as non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), a...
Inventiva Earnings Call Summary
The call was strongly focused on positive clinical, regulatory, commercial, and financing progress: NATiV3 is fully recruited with the final 72-week visit completed, phase II-B results were described as robust, the balance sheet was strengthened, and cash runway covers the expected Q4 2026 readout and potential 2027 filing. The principal negatives were the pending phase III outcome, known weight gain and edema effects, lower-end liver stiffness results, increased marketing and G&A expenses, and financing runway beyond Q2 2027 remaining conditional. Highlights significantly outweighed the stated challenges.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Inventiva remains on track to report NATiV3 top-line data in the fourth quarter of 2026 from the main cohort of 1,009 participants, is preparing for a potential NDA submission with the FDA in the first half of 2027, and is building for a potential commercial launch in 2028; the market potential is expected to exceed $15 billion by 2035. Current financing assumptions, existing resources, and completed financing transactions provide cash runway until the end of the second quarter of 2027, while, assuming full exercise of Tranche 3 warrants on the back of a positive top-line result and successful completion of Tranche C of the debt financing transaction, cash runway would extend to the start of the first quarter of 2028. The company secured new debt financing of up to EUR 130 million in three committed tranches, subject to conditions, with an initial drawdown of two tranches of EUR 75 million gross, plus an additional uncommitted tranche of up to EUR 20 million, and completed an underwritten public offering generating gross proceeds of EUR 103 million; it is not guiding on any future raises, top-line data contents, or what it expects over time for edema.
Inventiva Financial Statement Overview
Summary
Financial profile is high-risk: revenue deteriorated sharply in the latest year (~73% decline vs. prior year), losses widened, and cash burn remains large and persistent. Balance sheet flexibility is constrained by negative equity (2024–2025) alongside increased debt, which amplifies financing risk.
Income Statement
14Very NegativeBalance Sheet
18Very NegativeCash Flow
16Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 49.00K | 4.48M | 14.72M | 17.48M | 12.18M | 4.19M |
| Gross Profit | -2.56M | 1.57M | 9.20M | 17.50M | 11.18M | 3.18M |
| EBITDA | -37.34M | -133.10M | -92.36M | -102.04M | -57.70M | -52.27M |
| Net Income | -247.72M | -354.14M | -184.21M | -110.43M | -54.27M | -49.64M |
Balance Sheet | ||||||
| Total Assets | 251.21M | 249.51M | 118.97M | 69.56M | 116.00M | 121.98M |
| Cash, Cash Equivalents and Short-Term Investments | 166.13M | 230.87M | 96.56M | 26.99M | 87.02M | 86.55M |
| Total Debt | 66.66M | 59.86M | 54.33M | 37.49M | 34.51M | 10.12M |
| Total Liabilities | 192.21M | 278.03M | 225.61M | 101.59M | 70.53M | 33.12M |
| Stockholders Equity | 59.00M | -28.52M | -106.65M | -32.03M | 45.48M | 88.87M |
Cash Flow | ||||||
| Free Cash Flow | -109.71M | -105.13M | -86.26M | -82.15M | -45.49M | -48.16M |
| Operating Cash Flow | -109.35M | -104.88M | -85.93M | -81.61M | -44.93M | -47.63M |
| Investing Cash Flow | -44.57M | -133.19M | 8.74M | -7.73M | 8.87M | -1.79M |
| Financing Cash Flow | 196.96M | 241.29M | 145.59M | 29.08M | 37.27M | 25.45M |
Inventiva Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:IVA, the sentiment is Negative. The current price of 3.18 is above the 20-day moving average (MA) of 2.99, below the 50-day MA of 3.33, and below the 200-day MA of 4.16, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 51.76 is Neutral, neither overbought nor oversold. The STOCH value of 78.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:IVA.
Inventiva Risk Analysis
Inventiva disclosed 83 risk factors in its most recent earnings report. Inventiva reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
1 New RiskInventiva Peers Comparison
Overall Rating
- FR:IVA50Neutral
FR:POXEL46Neutral
FR:ABVX44Neutral
FR:GNFT44Neutral
FR:ALVAL37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| FR:IVA | 50Neutral | EUR 760.35M | -6.00 | -1625.48% | ― | -99.64% | 68.67% |
| FR:POXEL | 46Neutral | EUR 8.87M | -0.43 | 33.88% | ― | ― | ― |
| FR:ABVX | 44Neutral | EUR 6.92B | -16.78 | -85.88% | ― | ― | ― |
| FR:GNFT | 44Neutral | EUR 541.90M | -5.32 | 279.22% | ― | 27.70% | -162.89% |
| FR:ALVAL | 37Underperform | EUR 22.31M | -2.13 | -87.66% | ― | 183.47% | 57.15% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FR:IVA | Inventiva SA | 3.18 | -0.34 | -9.66% | |
| FR:GNFT | Genfit SA | 10.86 | 7.31 | 205.92% | |
| FR:ABVX | Abivax SA | 79.05 | -4.25 | -5.10% | |
| FR:POXEL | Poxel SA | 0.17 | -0.17 | -50.30% | |
| FR:ALVAL | Valbiotis SA | 0.63 | -0.01 | -0.95% |
Inventiva Corporate Events
Inventiva Showcases New Lanifibranor Data as Pan-PPAR MASH Strategy Advances
Inventiva will present three new scientific abstracts at AASLD The Liver Meeting 2026 detailing how its investigational MASH therapy lanifibranor exerts balanced activation of the three PPAR isoforms across multiple hepatic cell types implicated in f...
Inventiva Extends Cash Runway as Phase 3 MASH Trial Nears Key Readout
Inventiva reported a first-half 2026 net loss of €69.5 million as it ramped up spending on the Phase 3 NATiV3 trial of lanifibranor in MASH and related pre-commercial activities. The company ended June with €166.1 million in cash and S...
Inventiva Highlights Lanifibranor’s Metabolic and Cardiovascular Benefits in MASH
Inventiva reported new Phase 1 and Phase 2 clinical data, along with preclinical results, showing that lanifibranor improves insulin sensitivity, glycemic control, lipid parameters and key cardiovascular risk factors in patients with MASH, including...
Inventiva Hits Phase 3 Milestone as MASH Drug Lanifibranor Nears Key Readout
Inventiva has completed the final 72-week visit for the last patient in its pivotal NATiV3 Phase 3 trial of lanifibranor in adults with non-cirrhotic MASH and moderate to advanced fibrosis, after enrolling 1,009 patients in the main cohort and 410 in...
Inventiva Taps Veteran Operator as It Gears Up for Potential MASH Drug Launch
Inventiva has appointed industry veteran Chris Benecchi as Chief Operating Officer to steer operational preparations ahead of key Phase 3 results for its lead MASH candidate lanifibranor, expected in late 2026. The move signals the company’s tr...
Inventiva Corrects Financing Disclosure and Extends Cash Runway as MASH Program Advances
Inventiva reported preliminary first-half 2026 figures showing cash and cash equivalents of €166.1 million plus €67.8 million in short-term deposits, reflecting recent equity and debt financing transactions and an optimization of its capi...
Inventiva strengthens cash position but flags funding gap amid phase 3 MASH push
Inventiva reported preliminary first-half 2026 figures showing cash and cash equivalents of €166.1 million and €67.8 million in short-term deposits, underpinned by recent equity and debt financings and an early repayment of its European I...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 27, 2026